LONDON, Jan 20 (Reuters) – the international charity
Medecins Sans Frontieres urged drugmakers GlaxoSmithKline
and Pfizer on Tuesday to slash the price of
their pneumococcal vaccines to $5 per child in poor countries.
In a report on vaccine prices ahead of an international
donor conference in Berlin at the end of January, MSF slammed
Big Pharma companies and said the cost of vaccinating a child in
the world’s poorest countries was now 68 times higher than in
LONDON, Jan 19 (Reuters) – Peer pressure from radicalised
fighters in Syria and Iraq is more influential in attracting new
recruits from Europe than Islamic State (IS) propaganda,
according to British experts.
The International Centre for the Study of Radicalisation and
Political Violence (ICSR), in a study to be released next month,
found that peer groups and kinships were crucial in luring young
fighters, rather than IS videos and Internet messages.
LONDON (Reuters) – Health authorities launched an 11.5 million pounds ($17.4 million) plan on Monday to tackle Britain’s persistent tuberculosis (TB) problem, seeking to wipe the contagious lung disease out altogether.
Britain has one of the highest TB rates in western Europe and London is known as the continent’s “TB capital”.
LONDON (Reuters) – Britain’s infamous “Beagle 2″ spacecraft, once dubbed “a heroic failure” by the nation’s Astronomer Royal, has been found on Mars — 11 years after it went missing searching for extraterrestrial life.
Beagle 2, part of the European Space Agency’s Mars Express mission, had been due to land on Mars on Christmas Day 2003, but went missing on December 19, 2003. Until now, nothing had been heard from it since then.
LONDON, Jan 16 (Reuters) – GlaxoSmithKline is
feeling the heat from the rapid growth in electronic cigarettes,
with enthusiasm for the nicotine delivery devices dampening
sales of the British drugmaker’s patches and gum, its chief
In an interview with Reuters, Andrew Witty also said he and
his team had spent “a few days” exploring whether the drugmaker
should compete directly by becoming an e-cigarette maker, but
had swiftly decided against it.
LONDON (Reuters) – Scientists have identified the crucial genetic mutations that cause a common heart condition called dilated cardiomyopathy (DCM), paving the way for more accurate diagnosis and screening of high-risk patients.
In a study of more than 5,000 people, researchers sequenced the gene encoding the muscle protein “titin”, known to be linked to this leading cause of inherited heart failure, to try to find which variations in it caused problems.
LONDON (Reuters) – Scientists have found a mechanism that kicks in when the body is cooled and prevents the loss of brain cells, and say their find could one day lead to treatments for brain-wasting diseases such as Alzheimer’s.
Studying mice, the researchers were able to simulate the effects of body cooling and pick apart the workings of a so-called “cold-shock” protein in the brain, RBM3, which has previously been linked with preventing brain cell death.
LONDON (Reuters) – Helping patients with chronic fatigue syndrome to overcome their fears that exercise or activity will make their symptoms worse is one of the most important factors behind therapies that can make them better, scientists said on Wednesday.
Presenting an analysis on a trial showing how cognitive behavior therapy (CBT) and graded exercise therapy (GET) help reduce fatigue and improve physical function in people with chronic fatigue syndrome (CFS), the researchers said misguided but understandable fears about being active were key.
LONDON, (Reuters) – Developing and bringing to market effective Ebola vaccines requires extreme measures and unprecedented international cooperation, global health experts said on Monday.
In an interim report on a roadmap for vaccines against the current and any future outbreaks of the deadly virus, infectious disease specialists Jeremy Farrar and Mike Osterholm said the scope of effort was “too complex for any single government, organization or company”. They called for sustained public-private sector partnership and commitment.
LONDON, Jan 9 (Reuters) – The website of a global
partnership formed to wipe out deadly meningitis epidemics in
sub-Saharan Africa is closing down with a simple message: “Thank
you and goodbye!”.
Barely five years after the team began rolling out a
tailor-made vaccine in Africa’s “meningitis belt”, the disease
has all but disappeared there and the Meningitis Vaccine Project
(MVP) is closing down after pioneering what may be a model for
tackling infectious diseases in developing countries.